Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MedMira Inc V.MIR

Alternate Symbol(s):  MMIRF

MedMira Inc. is a Canada-based biotechnology company. The Company, through its subsidiaries, is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The Company invests in research in order to maintain and expand its position in the global diagnostics market. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. The Company is the developer and owner of Rapid Vertical Flow (RVF) Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as Human Immunodeficiency Virus (HIV), Syphilis and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal, Multiplo and Miriad brands in global markets. The Company's manufacturing facilities are located in Halifax, Nova Scotia, Canada.


TSXV:MIR - Post by User

Bullboard Posts
Comment by OnTheSceneon May 22, 2020 11:46am
207 Views
Post# 31061089

RE:RE:More news...

RE:RE:More news...Google Translate

The CE approval for MedMira's Covid19 antibody test is an important milestone and shows once again that the company has the right product at the right time at the start. No wonder the share rose 40% yesterday with massive sales and is headed north again after a small consolidation. So you can become a takeover candidate ...
 
MedMira with the next bang and European CE approval !: MedMira receives important European CE approval for Corona rapid test and inclusion in the German DIMDI! Share rises massively with huge sales. | wallstreet-online.de
 
 MedMira receives the important CE approval in Europe and is accepted into the German Institute for Medical Documentation and Information. A huge step and now the FDA approval is pending in the USA. Because that would be an even more important step, since this is the market on the doorstep. However, I am very confident that this will be possible in the next few weeks. The time frame for the FDA's EUA approval process is not strictly specified, but MedMira is ready to meet all of the FDA's requirements in a timely manner. This shouldn't be a problem either, as MedMira has previously received the European CE, US FDA approvals, Health Canada and the CFDA in China for their RVF-based Reveal HIV antibody tests and EU approval for their Multiplo TP / HIV Quick test.
  
 The production capacities for the start are available and are to be expanded further. I could also imagine that you use licensed and third-party manufacturers because you urgently need tests around the world, especially at airports in the future if flying is to start again properly. This is exactly what MedMira's test would be perfect for, since the entire process takes less than 3 minutes and the actual result is less than 1 minute with + 99% reliability. The world's largest pharmaceutical company Roche has also received approval for a test, which makes sense for large clinics and e.g. in the university hospital in Munich. He needs a CHF 2 million basic device on which tests are then run. Makes sense in clinical use and for large group tests, however, mobile impossible. Exactly there I see the advantage and a huge field of application of MedMira in the mobility of the test, the low acquisition costs (the test will cost around 40-50 CHF), the very high reliability of over 99% and very important the speed! (Airport, customs, entry into foreign countries, train stations etc.). Gilead is starting her drug Remdesivir but has no quick test. Before you can treat, you have to be able to test and do it all the time.
  
 MedMira with the next bang and European CE approval !: MedMira receives important European CE approval for Corona rapid test and inclusion in the German DIMDI! Share rises massively with huge sales. | wallstreet-online.de - Full article at:
 https://www.wallstreet-online.de/news/12553078-medmira-naechstem-paukenschlag-europaeischer-ce-zulassung-medmira-wichtige-europaeische-ce-zulassung-corona-schnelltest-aufnahme-deutsche-dimdi-aktie- massive huge sales
 I think that MedMira has a huge future ahead of it and it won't be long before the first large companies at MedMira knock on the door for the technology. A takeover comes into consideration for me at the earliest at> 3 CAD. Why? Quite simply calculated: I assume a production of approx. 10 million rapid tests per year that MedMira can handle together with third-party manufacturers. This means the company has net sales of approximately $ 250 million a year. With a profit margin of 70% for taxes, around USD 175 million remains. If we discount a safety margin of 40% here, we are still rounded at USD 100 million. A price-earnings ratio of 15 is very likely for such a company, which brings us to a valuation of $ 1.5 billion ($ 15 x $ 100 million). At the current USD-CAD exchange rate, this results in a valuation of around CAD 2.1 billion, which for around 659 million shares results in around CAD 3.20 per share. I know for you as a reader these are castles in the air, fantasy calculations etc. However, I am always concerned with what can go where and what a calculated value results under the prevailing market and competitive conditions. Important: these are my own thoughts and number games. Everyone has to know what he is doing! 
Bullboard Posts